Area of research
Hepatology · Epidemiology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, and Cholangiocarcinoma and Gallbladder Cancer Studies.
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.
Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.
In vitro and in silico assessment of a multi side-hole catheter for transcatheter endovascular treatments on arterial bifurcations
ATF4 programs proline-dependent immune evasion in β-Catenin-driven hepatocellular carcinoma
Bone mineral density does not predict overall survival in patients with advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial.
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study.
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma
Transarterial chemoembolisation with irinotecan (irinotecan-TACE) as salvage or post-inductive therapy for colorectal cancer liver metastases: effectiveness results from the CIREL study
Expression landscape of epigenetic genes in human hepatocellular carcinoma.
1494P Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the combined China extension and global cohorts in the phase III HIMALAYA study
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis.
Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?
Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis
Reply to: "Ruptured HCC: An entity in exile from the EASL Clinical Practice Guidelines!": Ruptured HCC: Not exiled, but navigating an evidence vacuum.
MORPHEUS-Liver provides a way forward in expanding the immunotherapy options for hepatocellular carcinoma.
Response evaluation to systemic therapy in HCC: Current challenges and future perspectives.
Pan-microbial serological repertoire as a biomarker of immunotherapy response in hepatocellular carcinoma.
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial.